More on Vermillion (VRML): Q3 beats bottom line consensus on lower-than-anticipated losses....
Monday, November 12, 2012, 4:57 PM ETMore on Vermillion (VRML): Q3 beats bottom line consensus on lower-than-anticipated losses. Revenue was flat on a Y/Y basis, while earnings got a big boost from better cost controls. Operating expenses decreased by nearly half as compared to the prior year period, driven by lower clinical trial costs, fewer legal expenses and ongoing cost containment initiatives. Shares +7.5% AH.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles